

Certificate of Analysis

| Catalog Number | BP15256 |
|----------------|---------|
| Product Name | SH5-07 |

Physical and Chemical Properties

| CAS No. | 1456632-41-9 |
|--|--|
| Chemical Formula | C29H28F5N3O5S |
| Molecular Weight | 625.61 |
| Solubility | H2O: Insoluble DMSO: 50 mg/mL (79.92 mM), Need ultrasonic |
| Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
| Chemical Structure OR Tested Image | OH OH NH F F ON N O |

Product Information

| Description | SH5-07 is a hydroxamic acid-based Stat3 inhibitor (IC50: 3.9 $\mu M).$ |
|--------------|--|
| Targets&IC50 | STAT3:3.9 µM (cell free) |

| In vitro | SH5-07 is a hydroxamic acid analog of BP-1-102. SH5-07 dose-dependently inhibits Stat3 activity (IC50: $3.9\pm0.6~\mu M$ in in vitro assay). It preferentially inhibits Stat3:Stat3 DNA-binding activity, ahead of inhibiting Stat1:Stat3 activity, with minimal effects on Stat1:Stat1 activity. SH5-07 binds Stat3, disrupts Stat3 association with growth factor receptor, and thereby inhibits Stat3 phosphorylation. It induces antitumor cell effects against malignant cells harboring constitutively-active Stat3. SH5-07 inhibits the expression of known Stat3-regulated genes. Bcl-xL, Bcl-2, c-Myc, Survivin, Cyclin D1, and Mcl-1 expression is reduced in response to 24 h, 5 μ M SH5-07 treatment. |
|----------|---|
| In vivo | Tail vein injection or oral gavage delivery of SH5-07 inhibits the growth of 90-150 mm^3 established subcutaneous mouse xenografts of human glioma (U251MG) and breast (MDA-MB-231) tumors that harbor aberrantly-active Stat3, associated with decreased Mcl-1, c-Myc, and Cyclin D1 expression. No significant changes in body weights, blood cell counts, or the gross anatomy of organs, or obvious signs of toxicity are observed. |

Analytical Data

| HPLC | Shows Min >99% purity |
|---------------------------------|--|
| H-NMR | Consistent with structure |
| Stability and Solubility Advice | Information on product stability, especially in solution, has rarely been reported and in most cases we can only provide a general guideline. We recommend that once the stock solution has been prepared, it be stored in equal quantities in sealed vials and used within 1 month. Avoid repeated freezing and thawing cycles. Storage conditions for some special products should be referred to their storage details. |

Purdue Bioscience Inc.

750~50 th~St,~Brooklyn,~NY~11220,~USA

http://www.purduebio.com

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022